金财互联(002530) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 301,149,597.35, representing a 22.85% increase compared to CNY 245,140,029.97 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 8,925,726.14, an improvement of 77.54% from a loss of CNY 39,736,540.48 in the previous year[4] - The net profit for Q1 2023 was a loss of CNY 9,897,782.60, compared to a loss of CNY 36,512,573.84 in Q1 2022, indicating an improvement in performance[20] - The net profit for Q1 2023 was -6,404,105.35 CNY, compared to -40,932,490.29 CNY in the same period last year, showing a significant improvement[22] - The total profit for Q1 2023 was -2,009,025.88 CNY, compared to -39,531,351.68 CNY in Q1 2022, indicating a reduction in losses[22] - The basic and diluted earnings per share for Q1 2023 were both -0.01 CNY, an improvement from -0.05 CNY in Q1 2022[23] Cash Flow - The net cash flow from operating activities was a negative CNY 76,202,413.73, which is a 22.41% improvement compared to a negative CNY 98,205,879.86 in the same period last year[4] - Cash flow from operating activities showed a net outflow of -76,202,413.73 CNY, an improvement from -98,205,879.86 CNY in the previous year[23] - Cash flow from investing activities generated a net inflow of 34,761,369.44 CNY, compared to a net outflow of -176,835,761.71 CNY in Q1 2022[24] - Cash flow from financing activities resulted in a net inflow of 28,308,847.63 CNY, contrasting with a net outflow of -34,577,046.19 CNY in the same quarter last year[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,649,624,711.56, a decrease of 1.33% from CNY 2,685,321,487.19 at the end of the previous year[4] - The total assets as of March 31, 2023, were CNY 2,649,624,711.56, down from CNY 2,685,321,487.19 at the beginning of the year[19] - The total liabilities decreased to CNY 1,099,055,033.80 from CNY 1,124,397,704.08, reflecting a reduction of 2.2%[19] - The company reported a total equity of CNY 1,550,569,677.76, down from CNY 1,560,923,783.11 at the beginning of the year[19] Operating Performance - The total operating revenue for Q1 2023 was CNY 301,149,597.35, an increase of 22.9% compared to CNY 245,140,029.97 in the same period last year[20] - The total operating costs for Q1 2023 were CNY 311,047,379.95, up from CNY 281,652,603.81 in Q1 2022, reflecting an increase of 10.4%[20] - The company reported operating income of -1,479,244.97 CNY for Q1 2023, an improvement from -39,948,902.35 CNY in Q1 2022[22] Investment and Financing - The company reported an investment income of CNY 4,366,244.64, a significant increase of 2448.13% from a loss of CNY 185,945.57 in the same period last year[9] - The net cash flow from investing activities was CNY 34,761,369.44, a 119.66% increase compared to a negative CNY 176,835,761.71 in the previous year[10] - The company recognized investment income from joint ventures of 2,425,973.59 CNY, compared to a loss of -571,505.29 CNY in the previous year[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 57,111[11] Research and Development - The company’s R&D expenses for Q1 2023 were CNY 26,081,390.41, slightly down from CNY 26,742,261.33 in the previous year[20] Cash and Equivalents - Cash and cash equivalents at the end of Q1 2023 amounted to CNY 360,850,668.52, slightly down from CNY 365,485,344.57 at the beginning of the year[16] - The total cash and cash equivalents at the end of Q1 2023 were 317,088,066.14 CNY, down from 330,266,076.22 CNY at the beginning of the quarter[24] Accounts Receivable and Inventory - Accounts receivable increased to CNY 284,719,395.71 from CNY 260,929,667.84, representing a growth of 9.1%[16] - Inventory levels rose to CNY 399,510,400.55, compared to CNY 396,631,699.12 at the start of the year, showing a marginal increase[17] Loans - The company experienced a 185.00% increase in long-term loans, amounting to CNY 54,414,086.47, due to increased borrowing in the heat treatment segment[8] Government Subsidies - The company received government subsidies totaling CNY 2,444,171.99, which are closely related to its normal business operations[5] Return on Equity - The weighted average return on equity improved by 1.69 percentage points, reaching -0.65% compared to -2.34% in the previous year[4]